Home › Mutual Funds › Nippon India Mutual Fund › Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl
Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

飞鱼电竞买外围软件下载

Add To Compare

previously known as Nippon India Pharma Dir DR until

103.419 (-0.048%)
NAV on September 09, 2022
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 4,588 cr
Turnover Ratio 55.36%
Expense Ratio 1.06%
Exit Load 1.00% if redeemed within
1 Months 0.00% if redeemed after 1 Months
Returns
  • 1M: 0.10%
  • 1Y: -7.08%
  • 3M: 5.50%
  • 3Y: 29.47%
  • 6M: -0.03%
  • 5Y: 20.66%
Min Investment 5,000
Buy Now Start SIP
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 17 years) Kinjal Desai (Since over 4 years)
ISIN INF204K01I43
Fund Family Nippon India
P/E Ratio 32.06
P/B Ratio 4.31
Launch Date January 01, 2013
Benchmark S&P BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs S&P BSE Healthcare TR INR

Alpha 7.52
Beta 0.91
R-Squared 95.01
Info Ratio 1.51
Tracking Err 5.09
Sortino 2.618
Sharpe 1.154
Std Dev 21.026
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Dividends that would otherwise be paid out to investors are instead used to purchase more units in the fund. Not as tax efficient as Growth.

View Factsheet
-
Best Sector Healthcare Funds
NAME LATEST
NAV 		RETURNS
1y     		FUND
ASSETS 		Expense
RATIO 		RISK
Sbi
SBI Healthcare Opportunities Fund Direct Growth
240.137 -6.70% 1,675 cr 1.07% -
Mirae
Mirae Asset Healthcare Fund Direct Growth
23.187 -7.21% 1,723 cr 0.62% -
Icici
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
20.090 -9.95% 2,465 cr 1.21% -


Other plans of Nippon India Pharma


Other Equity funds by Nippon India

Data Partner
Click here to visit AMC website and
read all scheme related documents Nippon India Fund